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Abstract. The single-dose pharmacokinetics of recombi- 
nant human erythropoietin (rHuEPO) given SC was inves- 
tigated in 20 patients aged 7 -20  years at different stages of 
chronic renal failure. In a pilot study we confirmed the 
lower bioavailability of the drug in 2 children when given 
SC compared with the IV route (24% and 43%, respec- 
tively). Following administration of 4,000 units/m2, 
rHuEPO SC effective serum erythropoietin concentrations 
increased from a mean baseline level (_+ SD) of 23 ___ 13 
units/1 to a mean peak concentration of 265 _+ 123 units/l, 
which was reached after 14.3 ___ 9.4 h, followed by a slow 
decline until baseline values were attained at 72 h. Mean 
residence time was 30 +9 h and mean elimination half- 
time 14.3 +7 h. The single-dose kinetics of SC rHuEPO in 
children with different degrees of renal failure are compa- 
rable to those in adult patients. Possibly, the higher effi- 
cacy of SC rHuEPO in patients with renal anaemia com- 
pared with IV rHuEPO is related to its prolonged action. 
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Introduction 
Anaemia is a predictable complication of chronic renal 
failure (CRF) in children [1, 2]. Its mechanisms are com- 
plex, but insufficient production of erythropoietin (EPO) in 
relation to the degree of anaemia ppears to be the most 
important factor. The gene for human EPO has been cloned 
and recombinant human EPO (rHuEPO) is available for 
clinical use [3]. The efficacy of EPO in correcting renal 
anaemia in adults and children [4-10] with end-stage renal 
disease has been demonstrated. However, the optimum 
route of administration and dosage of rHuEPO are still 
debated. 
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After IV administration to adult patients with CRF, the 
elimination half-life (tl/2) of rHuEPO is relatively short 
(5 -12 h) compared with that following SC application 
[11-14]. This route may be preferable to the IV route, 
allowing less frequent application and injections at home. 
In adults with CRF maintained on SC rHuEPO, the drug 
appears to be more effective than when given IV, despite 
the lower bioavailability [11, 13, 15, 16]. For children, SC 
administration appears to be of special benefit in pretermi- 
nal CRF and during continuous ambulatory peritoneal 
dialysis (CAPD) [4, 9], where a permanent vascular access 
is not available. 
The pharmacokinetics of rHuEPO have been studied in 
adult patients with CRF [14, 17-19] since sensitive and 
specific assays for the hormone have become available 
[20]. In this paper we report the results of a single-dose 
pharmacokinetic study of SC rHuEPO in paediatric CRF 
patients elected for long-term treatment with the drug. 
Patients and methods 
Patients 
Twenty paediatfic patients with CRF were investigated. The study was 
approved by the local ethics committee. Informed consent was obtained 
from the patients or their parents. Table 1 presents he relevant clinical 
data. The primary kidney disorder was congenital or hereditary in 
14 patients and acquired in 6 children. No child had previously been 
treated with rHuEPO. All patients were in a stable clinical condition 
without infection. Liver function tests were normal. The mean base 
haemoglobin level was 7.0+ 1.0 (range 5.2-9.0) g/dl. 
At the time of the study, 6 patients were undergoing regular hae- 
modialysis, 7 were being treated with CAPD and 7 were on conservative 
treatment [preterminal CRF, mean serum creatinine l vel 6,3 (range 
3.2-12.0) mg/dl]. Dialysis was started at a mean of 28 (range 0.5-100) 
months prior to the pharmacokinetic investigation. I  patients on CAPD, 
no peritonitis was observed inthe 3 months prior to the start of rHuEPO 
therapy. 
Study design 
In a pilot study we compared the response of 2 patients with CRF on 
dialysis, a boy and a girl, both 15 years old, to a rHuEPO dose of 4,000 
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Table i. Clinical characteristics of 20 paediatric patients with chronic 
renal failure receiving 4,000 units recombinant human erythropoietin 
(rHuEPO)/m 2
Mean • SE Range 
Age(years) 12.7 • 3.9 6.8 - 19.9 
Weight (kg) 34.0 • 13.9 17.0 - 59.8 
Height (cm) 140.6 • 111 -181 
Body surface area (m 2) 1.16 • 0.34 0.68- t.77 
units/m 2 given as a SC injection in the thigh and 1 week later as an IV 
bolus. This pilot study allowed investigation of EPO distribution, bio- 
availability and other pharmacokinetic parameters. In the main study we 
gave the same dose of rHuEPO SC to the rest of the patients, rHuEPO 
was supplied as a sterile buffered solution (1 ampoule = 4,000 units/ml, 
Cilag, Sulzbach, Germany). 
For the determination f serum EPO concentrations, blood samples 
were taken from an indwelling venous catheter immediately before and 
10, 20, 30 and 60 min and2, 3, 4, 5, 8, 12, 16, 18, 20, 24, 30, 36, 48 and 
72 h (hi some children 96 h) after rHuEPO application. The centrifuged 
serum samples were stored at -20~ until analysis. In haemodialysed 
patients the drug was administered immediately after termination of the 
session and blood was analysed only during dialysis-free intervals. The 
radioimmunoassay used for EPO estimation had been described pre- 
viously [20]. It has a lower detection limit of 5 units/l with an interassay 
coefficient of variation (CV) of 6.7% for an EPO concentration f 44 
units/l. In normal children below 15 years of age, serum EPO levels 
determined by the same assay range between 7 and 47 units/1 (mean 18.8 
units/t); in adolescents up to the age of 20 years they are between 13 and 
36 units/1 (mean 21 units/l) [21]. 
Data analysis 
Pharmacokinetic parameters were estimated using standard methods. 
Both model-independent a d model-dependent approaches were used for 
the pharmacokinetic analysis of data obtained from the two modes of 
rHuEPO administration. The base level of serum EPO was subtracted 
from the measured EPO concentration profile before a pharmacokinetic 
model was fitted to the concentration versus time data. 
Pharmacokinetic modelling. Following an IV bolus injection, several 
one-, two- and three-compartment open models (COM) using exponen- 
tial functions were applied to describe EPO serum concentrations. After 
SC administration, a one-COM with first-order or zero-order input was 
applied for prediction of the EPO concentration profile where TKO is the 
unbiased estimation of the time at which peak concentration occurred 
(tin,x) [22]. All non-linear regression analyses for the estimation of the 
kinetic parameters were performed by MKMODEL, an extended least 
squares modelling programme developed by Holford [23]. 
Total clearance (C)was estimated by non-compartmental analysis 
from the area under the serum concentration versus time curve (AUC) 
according to the equation: C = f x dose/AUC, where f is the fractionof 
the dose absorbed (bioavailability). Mean residence time (MRT), i. e. the 
average time one molecule of EPO remains in the central compartment, 
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Fig. 1. Serum concentration ferythropoietin (EPO) versus time profile 
after IV and SC application of 4,000 units recombinant human EPO 
(rHuEPO)/m 2in 2 adolescents reated with continuous ambulatory peri- 
toneal dialysis ( A ) and haemodialysis ([]), respectively 
was calculated by using the equation: MRT = AUMC/AUC, where 
AUMC is the model-independent area under the first moment curve. 
The model-independent AUC up to the last measured serum concen- 
tration was estimated by using the linear trapezoidal rule with extrapola- 
tion to infinity (,,~), determined by using the ratio of the least measured 
serum concentration over the terminal rate constant (LM/lz); lz was 
estimated by unweighed linear egression of log Cp (units/l) versus time 
for the last 3 or 4 data points, tl/2 was defined as ln2/lz (= 0.683/tz). 
Statistics. Mean standard eviation and CV were determined by using 
standard equations [24]. 
Results 
SC versus IV rHuEPO disposition 
F igure 1 and Tab le  2 demonstrate  the di f ferences in the 
disposi t ion and pharmacok inet ics  o f rHuEPO when g iven  
to the same 2 patients by  the SC and later by  the IV  route. 
Fo l low ing  the IV  bolus inject ion,  the serum EPO concen-  
trat ion versus t ime prof i les were  best character ized by a 
two-COM accord ing to the results o f  MKMODEL fit 
statistics (Log L ike l ihood,  Schwartz  Cr i ter ion,  WSSR)  as 
demonstrated by  using MODELTEST [23]. 
When the drug was g iven  by the SC route, the apparent 
peak serum concentrat ion (Cmax) was de layed and much 
lower  when compared  with the IV  appl icat ion.  The s low 
EPO release f rom the SC t issue stores produced an EPO 
Table 2. Comparison of pharmacokinetic parameters after application of 4,000 units rHuEPO/m 2by the IV and the SC route to 2 patients on dialysis 
aged 15 years 
Patient Appli- Cmax AUCoo C Vd r ~ f 
cation (units/l) (units/l per hour) (l/h) (1) (h) (%) 
1 (female, IV 2,225 20,187 0.277 0.0657 10.8 100 
weight 38.8 kg) SC 176 4,820 1.162 0.1111 3.0 23.9 
2 (male, IV 2,554 24,309 0.279 0.0484 10.9 i00 
weight 58.6 kg) SC 438 10,468 0.649 0.1552 15.4 43.1 
Vd, Volume of distribution; f, bioavailability; Cmax, peak sermn concentration; AUC, extrapolated area under the serum concentration versus time curve; 
C, clearance; tl/2, half-life 
Table 3. Pharmacoldnetic data of 4,000 units rHuEPO/m 2given SC to 20 
paediatric patients with chronic renal failure a
Non-compartmental an ysis 
Cmax (units/l) 265.4 + 123.5 
tmax (h) 14.3 -+ 9.4 
AUC ~" (units/l per hour) 7,684 + 3,141 
AUC-24 h (units/1 per hour) 3,731 + 1,603 
CIf (l/h) 0.6709 --+0.3699 
One-COM with zero-order input 
/lag (]1) 0.55 -Jc 0.83 
TKO (h) 14.1 -+ 9.4 
MRT (h) 29.7 -+ 9.2 
tl/a (h) 14.3 -+ 7.2 
trnax, Time at which peak concentration occurred; tlag, lag time; TKO, 
unbiased estimation of tmax; MRT, mean residence time 
a Mean ___ SD 
concentration-time profile resembling a one-COM with a 
zero-order input into the central compartment. The SC 
rHuEPO disposition in the 2 patients presented in Fig. 1 
was not as smooth as expected, but rather discontinuous. 
After Cmax was reached, EPO serum levels decreased but 
rose again between 20 and 30 h after application. 
SC rHuEPO disposition and kinetics in 20 patients 
with CRF 
Serum EPO base levels in the 20 patients tested were 
within the range of healthy subjects (mean 23+13 
units/mi) except in 1 subject (70 units/l). After SC admin- 
istration of 4,000 units rHuEPO/m 2, the mean serum EPO 
concentration i creased slowly with a mean lag time (tlag) 
of 0.55 h until a mean Cmax of 265 units/l was reached, with 
a mean tmax of 14.3 h (Table 3, Fig. 2). Subsequently, it 
decreased to 205 and 78 units/l after 24 and 48 h, respec- 
tively; 72 h after administration the mean serum EPO level 
almost reached the basal value (25 vs. 23 units/l, n = 5). In 
a few patients, slightly elevated EPO concentrations were 
observed up to 96 h. Additional pharmacokinetic results 
are presented in Table 3. No significant differences were 
found between the pharmacokinetic data of young and 
older children or between patients with preterminal and 
end-stage CRF. 
Discussion 
Both monophasic and biphasic serum concentration pro- 
files have been described in adults following the IV admin- 
istration of rHuEPO [13, 14, 17, 18, 25-27]. In a recent 
paper describing the pharmacokinetics of IV rHuEPO giv- 
en to nine children with end-stage renal disease, a mono- 
phasic profile was described; however, the curves pre- 
sented in that paper suggest rather a two-COM [28]. Curve 
fitting of the IV data from our children with CRF demon- 
strated that the two-COM is the most appropriate model. 
In contrast, SC administration of rHuEPO resulted in a 
completely different drug disposition and the pharma- 
cokinetics were characterized by a lower Cmax, a smaller 
AUC and a prolonged tl/2. For the interpretation of these 
data one should be aware that, strictly speaking, pharmaco- 
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Fig. 2. Serum EPO concentration versus time profile after SC application 
of 4,000 units rHuEPO/m 2 in 20 paediatric patients with chronic renal 
failure (mean _+ SEM) 
tion cannot be compared, because prolonged rug release 
from the SC tissue into the central compartment influences 
both disposition and kinetics of the drug. In addition, we 
often observed a discontinuous drug disposition after SC 
injection as if, for some reason, the drug transfer to the 
central compartment had been transiently interrupted. We 
believe that the one-COM with zero-order input is able to 
predict adequately the serum EPO concentration-time 
course after SC administration. 
Our results are similar to the pharmacokinetic data ob- 
tained by Boelaert et al. [12] after SC rHuEPO administra- 
tion in adult patients on CAPD; in the latter study, twice 
our dose, i.e. 300 units/kg (vs. 133 units/kg in our series), 
was given to adult CAPD patients, resulting in mean AUC 
and Cmax values which were about twice as high as in our 
patients. Macdougall et al. [11], who gave an rHuEPO dose 
(120 units&g) similar to that used in our study, observed a 
comparable mean AUC, but mean Cmax was only 176 
units/l and mean EPO levels remained above the baseline 
up to 96 h. Stockenhuber tal. [27], who injected 100 units 
rHuEPO/kg to adult patients on dialysis, reported Cmax and 
AUC values less than half of those observed in this study. 
In these studies, however, tl/2 was similar to our findings. 
In other pharmacokinetic studies, where smaller doses 
(40-50 units/kg) of SC rHuEPO were given to adult 
patients [14, 25, 29] or children [28], Cmax was relatively 
low and tmax was sometimes delayed up to 24 h. It should 
be stressed that our results obtained in CRF patients aged 
7 -20  years cannot be translated to younger children. 
The absolute bioavailability found in our pilot study 
after SC rHuEPO administration was in the range reported 
in adult patients with end-stage renal disease (21%-36%) 
[11, 14, 27]. In a recent paediatric study, it ranged between 
21% and 60% with a mean of 40%. The low bioavailability 
of rHuEPO compared with other hormones given SC (such 
as growth hormone [30]) may be due to the large size of the 
EPO molecule or to the presence of peptidases in the skin 
preventing absorption of the drug [31 ]. 
No significant difference was found in the decay of 
serum EPO between our patients with moderate (pretermi- 
nal) CRF and those with end-stage renal disease. This 
confirms the results of Kindler et al. [13] who investigated 
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the pharmacokinetics of IV EPO in adult patients with 
various degrees of CRF and concluded that EPO elimina- 
tion occurs mainly through non-renal mechanisms. 
Our study demonstrates that the single-dose pharma- 
cokinetics of rHuEPO in paediatric patients with CRF are 
similar to those observed in adult patients. Although the 
prolonged presence of high serum EPO levels after SC 
rHuEPO injection do not necessarily indicate a sustained 
stimulatory effect on the bone marrow, recent clinical stud- 
ies suggest that the rHuEPO requirement is less with the 
same dose given by the SC compared with the IV route 
[14, 15]. Our experience suggests that a single SC dose of 
150 units rHuEPO/kg applied once a week is sufficient o 
produce and maintain the required target haemoglobin 
levels in most children with CRF [10]. It remains to be 
investigated if a more frequent SC administration without 
changing the total dosing rate results in a higher efficacy of 
the drug and whether tl/2 is progressively shortened by 
repeated administration, as found in patients receiving 
EPO by the IV route [17, 32]. 
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